Medical Condition News

RSS

Depression is as much of a risk factor for mortality as smoking, says new study

A study by researchers at the University of Bergen, Norway, and the Institute of Psychiatry (IoP) at King's College London has found that depression is as much of a risk factor for mortality as smoking.

17 Nov 2009

American Heart Association supports ‘Healthy Choices for Healthy Children legislation'

The American Heart Association is joining efforts to decrease and prevent childhood obesity through legislation that is being introduced today in the Ohio Senate and Ohio House of Representatives. The

17 Nov 2009

GlaxoSmithKline and bioMerieux to develop predictive test for breast cancer treatments

bioMerieux has signed an agreement with GlaxoSmithKline to develop a predictive test to help clinicians select the most appropriate treatment for different segments of breast cancer patients.

17 Nov 2009

Advanced BioHealing commences efficacy trial of Dermagraft in the treatment of VLUs

Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, announced that it has initiated a pivotal trial of Dermagraft® in subjects with venous leg ulcers (DEVO-Trial) to assess the product’s safety and efficacy in the promotion of healing venous leg ulcers (VLUs). Dermagraft is a bio-engineered skin substitute that assists in restoring damaged tissue and supports the body’s natural healing process.

17 Nov 2009

Genzyme and Isis Pharmaceuticals announce phase 3 study data of mipomersen

Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were presented today at the American Heart Association’s Scientific Sessions.

17 Nov 2009

Alkermes commences phase 2 study of ALKS 33 in patients with alcohol dependence

Alkermes, Inc. today announced the initiation of a phase 2 clinical study of ALKS 33, an investigational oral opioid modulator for the potential treatment of alcohol dependence and other central nervous system disorders. The study will assess the safety and efficacy of multiple doses of ALKS 33 in patients with alcohol dependence and is designed to further define the clinical profile of ALKS 33.

17 Nov 2009

New technology drives therapies for older patients, those with Alzheimer's

Technology advances are making life better for the elderly and those with Alzheimer's disease by allowing the older to stay in their homes and giving the ill a way to interact with society again.

17 Nov 2009

Ellipse Technologies' MAGEC Technology for spinal deformity treatment receives CE Mark

Ellipse Technologies, Inc. announced today it has received CE Mark (Conformité Européenne) for its MAGECTM Technology for the treatment of spinal deformity. The first application for this technology is for the treatment of spinal scoliosis in young children and teenagers. The CE Mark allows the Company to market the MAGEC System in the European Union and other countries that recognize the CE Mark for commercial distribution purposes.

17 Nov 2009

Oncolytics Biotech's REOLYSIN combined with paclitaxel and carboplatin well tolerated for advanced cancers

Oncolytics Biotech Inc. today announced updated results from a Phase I/II U.K. trial (REO 011) of REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced cancers in a poster presentation at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference being held in Boston, Massachusetts.

17 Nov 2009

Cancer pain drug market to be $3.7 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by the continued dominance of opioids that include immediate-release morphine and novel fast acting opioid reformulations, the cancer pain drug market will increase from $2.3 billion in 2008 to $3.7 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

17 Nov 2009

Non-clinical data from Cytokinetics' smooth muscle contractility program presented

Cytokinetics, Incorporated announced today that three abstracts summarizing non-clinical data regarding its smooth muscle contractility program were presented at the 2009 Scientific Sessions of the American Heart Association in Orlando, Florida.

17 Nov 2009

Atrium Medical presents interim results from its COBEST clinical study at the 2009 VIVA meeting

Atrium Medical Corporation is proud to announce the release of the interim results from the COBEST clinical study. This study is to evaluate the use of bare metal stents vs. balloon expandable covered stents for the treatment of aorto-iliac occlusive disease. Prof. Patrice Mwipatayi of Royal Perth Hospital, Australia, presented interim data on the Covered versus Balloon Expandable Stent Trial known as COBEST at the 2009 VIVA (Vascular InterVentional Advances) meeting in Las Vegas.

17 Nov 2009

Melanoma Institute director to present Phase 2 study data of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Professor John F. Thompson, MD, Professor of Melanoma and Surgical Oncology at the University of Sydney, Director of the Melanoma Institute Australia, and Lead Investigator of the Phase 2 study of PV-10 for Metastatic Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on November 21, 2009 in Berlin, Germany.

17 Nov 2009

YM BioSciences presents preclinical results of its small molecule VDA at the AACR-NCI-EORTC conference

YM BioSciences Inc., a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that preclinical results for CYT997 were presented today in a poster by Cytopia Limited at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts.

17 Nov 2009

Bayer's NEXAVAR approved in over 70 countries for the treatment of liver cancer

Bayer Inc. announced today that its international trial known as SHARP (Sorafenib HCC Assessment Randomized Protocol), led by Study Manager and Bayer Canada employee Tom Giannaris, has been selected as the winner in the 'Best International Trial' category for the Global Clinical Practice Journal Awards.

17 Nov 2009

Presentations to highlight durability and efficacy of urethral bulking agents

Uroplasty, Inc. (AMEX: UPI), a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment of voiding dysfunctions, today announced that nine abstracts outlining study results submitted by various researchers have been accepted for presentation at the 2010 Annual Meeting of the Society for Urodynamics and Female Urology (SUFU), February 23-27, 2010 in St. Petersburg, FL. Presentations accepted were for both Uroplasty's Urgent® PC Neuromodulation System and Macroplastique® urethral bulking agent products.

17 Nov 2009

Entellus Medical completes its Series D financing totaling $30MM

Entellus Medical, the Minnesota-based developer of novel, less invasive treatments for chronic conditions of sinusitis, has completed its Series D financing totaling $30MM. The Series D round was led by new investor Essex Woodlands Health Ventures and supported by existing investors Split Rock Partners and SV Life Sciences.

17 Nov 2009

Consortium to define new modalities for treating hypertension and associated vascular complications

Top Institute Pharma has formed a consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and Maastricht University to define new modalities for the treatment of hypertension (high blood pressure) and associated vascular complications such as heart and kidney failure, myocardial infarction and stroke.

17 Nov 2009

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

To highlight results of more recent research, the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference will host a press briefing on "Drugs in the Pipeline." Sara A. Courtneidge, Ph.D., D.Sc., professor and director of the Tumor Microenvironment Program, and director of academic affairs at the Burnham Institute for Medical Research, will moderate this press briefing.

17 Nov 2009

Global Alliance for Chronic Disease to fight against chronic non-communicable diseases

An alliance of institutions collectively managing an estimated 80 percent of all public health research funding worldwide today announced their first targets for concerted action in the fight against "chronic non-communicable diseases" (CNCDs).

17 Nov 2009

Medical Condition News

Depression is as much of a risk factor for mortality as smoking, says new study

American Heart Association supports ‘Healthy Choices for Healthy Children legislation'

GlaxoSmithKline and bioMerieux to develop predictive test for breast cancer treatments

Advanced BioHealing commences efficacy trial of Dermagraft in the treatment of VLUs

Genzyme and Isis Pharmaceuticals announce phase 3 study data of mipomersen

Alkermes commences phase 2 study of ALKS 33 in patients with alcohol dependence

New technology drives therapies for older patients, those with Alzheimer's

Ellipse Technologies' MAGEC Technology for spinal deformity treatment receives CE Mark

Oncolytics Biotech's REOLYSIN combined with paclitaxel and carboplatin well tolerated for advanced cancers

Cancer pain drug market to be $3.7 billion in 2018

Non-clinical data from Cytokinetics' smooth muscle contractility program presented

Atrium Medical presents interim results from its COBEST clinical study at the 2009 VIVA meeting

Melanoma Institute director to present Phase 2 study data of PV-10 for metastatic melanoma

YM BioSciences presents preclinical results of its small molecule VDA at the AACR-NCI-EORTC conference

Bayer's NEXAVAR approved in over 70 countries for the treatment of liver cancer

Presentations to highlight durability and efficacy of urethral bulking agents

Entellus Medical completes its Series D financing totaling $30MM

Consortium to define new modalities for treating hypertension and associated vascular complications

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

Global Alliance for Chronic Disease to fight against chronic non-communicable diseases

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News